1410993 / Impact of arterio-venous fistula flow on cardio-respiratory fitness

Impact of arterio-venous fistula flow on cardio-respiratory fitness (Study due to close 01/08/2018)

1511156 / REVIVED

This randomised controlled trial is designed to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) compared to optimal medical therapy alone for ischaemic left ventricular dysfunction. Patients with a poor left ventricular function with coronary artery disease have the potential to have ‘viable’ myocardium which will benefit from revascularisation. This study will assess whether compared to optimal medical therapy alone, PCI improves event free survival in these patients. A non-randomised registry will also follow patients with no viable myocardium and also patient deemed not suitable for PCI but who undergo Coronary Artery Bypass Graphing (CABG) or optimal medical therapy (OMT) alone. (Study due to close 30/04/2020)

1602208 / Symplicity Spyral

Global Clinical Study of Renal Denervation with the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients with Uncontrolled Hypertension in the Absence of Antihypertensive Medications (Study due to close 23/06/2020)

1604236 / RADIANCE-HTN” Study

The “RADIANCE-HTN” Study – A study of the ReCor Medical Paradise System in Clinical Hypertension (Study due to close 30/06/2018)


Study of the Optimum Duration of Acoustic Pulse Thrombolysis (APT) Procedure in the Treatment of Acute Submassive Pulmonary Embolism (OPTALYSE PE). (Study due to close 31/08/2019)

1705422 / IRONMAN

To establish in patients with chronic heart failure and iron deficiency whether treatment with intravenous iron is effective in reducing death due to cardiovascular problems, and hospitalisation due to heart failure. (Study due to close 01/08/2018)

1709501 / HFrEF

To evaluate the effect of treatment with omecamtiv mecarbil (OM) compared with placebo on the time to cardiovascular (CV) death or first HF event, whichever occurs first, in subjects with chronic HF with reduced ejection fraction (HFrEF) receiving standard of care (SoC) therapy. The primary hypothesis is that when added to SoC, OM is well tolerated and superior to placebo in reducing the risk of CV death or HF events in subjects with chronic HFrEF. Secondary hypotheses are that OM reduces the individual risks of:

• CV death
• HF hospitalization
• all-cause death

and improves symptoms in subjects with chronic HFrEF compared to placebo. (Study due to close 30/01/2019)

1711536 / DEFINE-PCI

Define-PCI .Physiologic assessment of coronary stenosis following PCI (Study due to close 30/09/2018)

1802589 / FDY-5301

Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction (Protocol No. FDY-5301-201)  (Study due to close 30/06/2018)

1803568 / The MPP VARR Study

The effect of MultiPoint™ pacing on reverse remodelling and the incidence of ventricular arrhythmias  (Study due to close 30/09/2018)

1806646 / AF-GEN-UK Study

Given the advances in the management of atrial fibrillation (an irregular heart rhythm), especially the new medications for stroke prevention, and the availability of new European Society of Cardiology (ESC) clinical guidelines, there is a need for the systematic collection of contemporary data regarding the management and treatment of atrial fibrillation.  There is currently a registry collecting data on how cardiologists (specialists in conditions of the heart) manage and treat patients with atrial fibrillation in 55 countries in Europe. Data is being collected on how cardiologists in the UK manage patients with atrial fibrillation.

However, in the UK, patients with atrial fibrillation are also managed by other doctors, particularly their general practitioner (GPs), accident and emergency (A&E) doctors (when admitted to hospital), stroke doctors (when atrial fibrillation is diagnosed after a stroke has occurred) and by acute medicine doctors (as atrial fibrillation is more common among people aged 65 years and older). This study will allow us to compare how patients with atrial fibrillation are managed by heart specialists (cardiologists) and other doctors (non-heart specialists). The purpose of collecting this data is to see if atrial fibrillation patients are managed in line with clinical guidelines.

In this UK extension study we will recruit up to 1650 atrial fibrillation managed by GPs, cardiologists, A&E, stroke, and acute medicine doctors. Demographic (e.g. age, sex, ethnicity etc) and clinical (e.g. other health problems, medications, operations etc) information will be recorded at baseline and then the patient will be followed up 12 months later to see how their healthcare is managed over time.  The follow-up will involve the patient visiting the hospital and/or review of their medical records and/or telephone call with the patient or their GP, according to the usual practice of the medical specialty who is managing the patient. (Study due to close 30/06/2018)

1810697 / Onyx in One

A Randomized Controlled Trial with Resolute Onyx in One Month Dual Anti Platelet Therapy for High-Bleeding Risk Patients (Study due to close 31/01/2019)